Following the appointment of a new new chief executive officer, Novo Nordisk A/S has said that it won't pursue large-scale mergers and acquisitions, yet it will consider opportunities to complement its own research. "If I were the incoming CEO, I'd say let's focus on our strengths," said Michael Kunst, a Munich-based partner with Bain & Company."I would argue that it's very important that you keep maintaining focus on your business where you have a leadership position and don’t get rattled by short-term challenges."